These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Treatment of multiple myeloma: an emphasis on new developments. Kyle RA; Vincent Rajkumar S Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696 [TBL] [Abstract][Full Text] [Related]
27. Clinical management of myeloma--state of the art. Harousseau JL Cancer Treat Rev; 2010 May; 36 Suppl 2():S1-2. PubMed ID: 20472182 [TBL] [Abstract][Full Text] [Related]
28. Treatment of myeloma in patients not eligible for transplantation. Jagannath S Curr Treat Options Oncol; 2005 May; 6(3):241-53. PubMed ID: 15869735 [TBL] [Abstract][Full Text] [Related]
29. Multiple myeloma: improved outcomes with new therapeutic approaches. Eshaghian S; Berenson JR Curr Opin Support Palliat Care; 2012 Sep; 6(3):330-6. PubMed ID: 22871979 [TBL] [Abstract][Full Text] [Related]
30. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Ludwig H; Khayat D; Giaccone G; Facon T Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003 [TBL] [Abstract][Full Text] [Related]
32. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586 [TBL] [Abstract][Full Text] [Related]
33. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? Palumbo A; Mateos MV; Bringhen S; San Miguel JF Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966 [TBL] [Abstract][Full Text] [Related]
34. Targeted therapy in multiple myeloma. Chng WJ; Lau LG; Yusof N; Mow BM Cancer Control; 2005 Apr; 12(2):91-104. PubMed ID: 15855892 [TBL] [Abstract][Full Text] [Related]
35. Future drug developments in multiple myeloma: an overview of novel lenalidomide-based combination therapies. Morgan G Blood Rev; 2010 Nov; 24 Suppl 1():S27-32. PubMed ID: 21126634 [TBL] [Abstract][Full Text] [Related]
36. Lenalidomide in multiple myeloma. Thomas SK; Richards TA; Weber DM Best Pract Res Clin Haematol; 2007 Dec; 20(4):717-35. PubMed ID: 18070715 [TBL] [Abstract][Full Text] [Related]
37. Novel agents for relapsed and/or refractory multiple myeloma. Thomas SK; Richards TA; Weber DM Cancer J; 2009; 15(6):485-93. PubMed ID: 20010168 [TBL] [Abstract][Full Text] [Related]
38. New therapies in multiple myeloma. Merchionne F; Perosa F; Dammacco F Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050 [TBL] [Abstract][Full Text] [Related]
39. Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide. Prince HM; Schenkel B; Mileshkin L Leukemia; 2007 Apr; 21(4):818-20; author reply 821. PubMed ID: 17301817 [No Abstract] [Full Text] [Related]
40. Current status of new drugs for the treatment of patients with multiple myeloma. Kenealy M; Prince HM Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]